By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Medical Answers > How long can you take Ibrance?

How long can you take Ibrance?

Answers by TheMediTary.Com - Last updated: 13-Jul-2023

Key Points

  • You will normally take Ibrance for 21 days in a row along with other medications, such as an aromatase inhibitor or fulvestrant. This cycle is repeated every 28 days as long as you are having a benefit and tolerate the side effects from the medicine.
  • Ibrance is used in women and men to treat advanced or metastatic hormone-receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer.
  • Side effects due to Ibrance may include increased infections, low red blood cell counts, tiredness, feeling sick to your stomach, hair loss, diarrhea and mouth sores, among others. Always discuss side effects with your doctor.

Ibrance (generic name: palbociclib) comes as a capsule or tablet taken by mouth to treat certain types of breast cancer. Ibrance is taken once a day for 21 days, with a 7 day break before starting again. You will repeat this 28-day cycle, based on effectiveness and tolerability, as long as your doctor prescribes it. Your doctor will prescribe other medications for you to use with Ibrance, such as an aromatase inhibitor or fulvestrant.

What is Ibrance used for?

Ibrance, from Pfizer, is used in adults to treat hormone-receptor-positive, HER2-negative breast cancer that is advanced or has spread in the body (metastatic).

  • It is used in combination with a hormonal therapy called an aromatase inhibitor for postmenopausal women or men who have not been treated with hormonal therapy before.
  • It is also approved for use in combination with fulvestrant for those whose disease worsens after using an aromatase inhibitor.

Aromatase inhibitors include medicines such as anastrozole (Arimidex), exemestane (Aromasin), and letrozole (Femara). In clinical studies, Ibrance was studied with letrozole in postmenopausal women but is approved by the FDA to be used with any aromatase inhibitor as first-line treatment. Fulvestrant (Faslodex) is considered an estrogen receptor antagonist.

What side effects can I expect with Ibrance?

Common side effects include:

  • fatigue (tiredness) and weakness
  • low red blood cell (anemia) or platelet counts
  • low white blood cell counts (neutropenia)
  • nausea
  • hair loss
  • abnormal liver tests
  • diarrhea
  • fever
  • loss of appetite
  • mouth sores

Ibrance may lower the ability of your body to fight off infections due to low white blood cell counts or cause lung problems such as inflammation (pneumonitis).

If you should vomit or miss a dose for any reason, do not take an additional dose of Ibrance. Take your next dose at the normal time.

Avoid consuming grapefruit juice and grapefruit products during your treatment with Ibrance. Grapefruit may cause your blood levels of Ibrance to rise and lead to worsened side effects.

In studies in patients taking Ibrance plus letrozole, 36% of patients (36 out of every 100) needed to have a dose reduction due to a side effect. About 9.7% (43 of 444) of patients permanently stopped therapy due to a side effect, such as low while blood cell count (neutropenia, 1.1%) and elevation of liver enzymes (alanine aminotransferase, 0.7%).

In studies looking at patients taking Ibrance plus fulvestrant, 36% of patients (36 out of every 100) needed to have a dose reduction due to a side effect. About 6% (19 of 345) of patients permanently stopped therapy due to a side effect such as fatigue (0.6%), infections (0.6%), and thrombocytopenia (0.6%).

Share this Article

Featured questions

  • How effective is Ibrance?
  • How common is hair loss with Ibrance?
  • Is Ibrance a form of chemo?
  • How does Ibrance kill cancer?
  • How much does Ibrance cost?
  • Can these drugs be used in Thalassemia patients?
  • How does Lupron (leuprolide) work for prostate cancer?
  • What is the consideration to use nifidepine over amlodipine?
  • Hypertrophic cardiomyopathy/mechanical heart valve?
  • I have been on 400mg of tramadol a day for 20 years, decided its time to come off them
  • Cetirizine - can cetirizine be taken for long periods of time?
  • In the 1960 and 1970 what was used to treat server asthma?
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch (Hydrocortisone topical)
Centrum Adult (Multivitamins and minerals)
Crovalimab
Cyltezo Prefilled Syringe (Adalimumab)
Zepbound Pen (Tirzepatide)
Mylanta One (Calcium carbonate, magnesium hydroxide, and simethicone)
Uretron Ds (Hyoscyamine, methenamine, methylene blue, phenyl salicylate, sodium biphosphate)
Medihoney Wound And Burn Dressing (Topical emollients)
Lidotrode
Libervant (Diazepam (buccal))
Moderna Covid-19 (Covid-19 (6m-11y) vaccine, moderna (2024-2025))
Beqvez (Fidanacogene elaparvovec)
Beqvez (Fidanacogene elaparvovec)
Beqvez (Fidanacogene elaparvovec)

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by